Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.34
+2.10 (3.49%)
At close: Feb 6, 2026, 4:00 PM EST
61.00
-1.34 (-2.15%)
After-hours: Feb 6, 2026, 7:39 PM EST
Cytokinetics Stock Forecast
Stock Price Forecast
The 17 analysts that cover Cytokinetics stock have a consensus rating of "Strong Buy" and an average price target of $85.24, which forecasts a 36.73% increase in the stock price over the next year. The lowest target is $41 and the highest is $136.
Price Target: $85.24 (+36.73%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 7 |
| Buy | 9 | 9 | 8 | 8 | 8 | 8 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 15 | 16 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $84 → $92 | Strong Buy | Maintains | $84 → $92 | +47.58% | Feb 3, 2026 |
| Barclays | Barclays | Buy Initiates $87 | Buy | Initiates | $87 | +39.56% | Jan 28, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $90 → $108 | Strong Buy | Maintains | $90 → $108 | +73.24% | Jan 21, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $95 | Buy | Reiterates | $95 | +52.39% | Jan 21, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $70 → $74 | Buy | Maintains | $70 → $74 | +18.70% | Jan 20, 2026 |
Financial Forecast
Revenue This Year
81.64M
from 18.47M
Increased by 341.94%
Revenue Next Year
122.59M
from 81.64M
Increased by 50.15%
EPS This Year
-6.48
from -5.26
EPS Next Year
-6.18
from -6.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 161.5M | 243.1M | ||||
| Avg | 81.6M | 122.6M | ||||
| Low | 68.6M | 53.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 774.3% | 197.8% | ||||
| Avg | 341.9% | 50.2% | ||||
| Low | 271.3% | -35.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.20 | -4.85 | ||||
| Avg | -6.48 | -6.18 | ||||
| Low | -7.05 | -7.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.